A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

Solid Tumors Clinical Trial

Official title:

A Phase I Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Patients With Locally Advanced Or Metastatic Solid Tumors.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04341259
• Other study ID #: YP40057
• Status: Completed
• Phase: Phase 1
• Start date: November 3, 2020
• Est. completion date: April 6, 2023

Study information

• Verified date: May 2023
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase I, Open-Label study designed to assess the pharmacokinetics (PK), safety and tolerability of ipatasertib in Chinese participants. Approximately 20 Chinese participants (12 PK-evaluable participants) with locally advanced or metastatic solid tumors for whom standard therapy either does not exist or has proven ineffective will be enrolled to provide sufficient data. Participants will receive a 400-mg ipatasertib dose (two 200-mg tablets) daily orally (PO). Participants deriving clinical benefit may be offered continued treatment with ipatasertib until disease progression, at the discretion of the investigator (as assessed by the investigator) or until the study is terminated by the Sponsor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: April 6, 2023
• Est. primary completion date: April 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically documented locally advanced or metastatic solid tumor that has progressed or failed to respond to at least one prior regimen.
• Not a candidate for regimens known to provide clinical benefit.
• Evaluable or measurable disease according to RECIST, v1.1.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.
• Life expectancy of >= 12 weeks.
• Adequate haematologic and organ function within 14 days prior to initiation of study treatment.
• Women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating eggs.
• Men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.
• Participants must reside in the People's Republic of China

Exclusion Criteria:

• Leptomeningeal disease as the only manifestation of the current tumor.
• Type 1 or 2 diabetes mellitus requiring insulin at study entry.
• Inability or unwillingness to swallow pills.
• Malabsorption syndrome or other condition that would interfere with enteral absorption.
• Known and untreated, or active CNS metastases (progressing or requiring anticonvulsants for symptomatic control).
• Congenital long QT syndrome or corrected QT interval (QTc) > 480 ms.
• Active congestive heart failure or ventricular arrhythmia requiring medication.
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring weekly paracentesis for 3 consecutive weeks prior to initiation of ipatasertib treatment.
• Severe infections within 4 weeks prior to screening including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
• Requirement for any daily supplemental oxygen.
• History of Inflammatory bowel disease or active bowel inflammation.
• Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy.
• Clinically significant history of liver disease, including viral disease or hepatitis,current alcohol abuse or cirrhosis.
• Known HIV infection.
• Active (chronic or acute) hepatitis C virus (HCV) at screening.
• Hepatitis B virus (HBV) infection (chronic or acute), defined as having a positive hepatitis B surface antigen (HBsAg) test or a positive quantitative HBV DNA test at screening
• Significant traumatic injury within 3 weeks prior to initiation of ipatasertib treatment.
• Major surgical procedure within 4 weeks prior to initiation of ipatasertib treatment.
• Treatment with chemotherapy, immunotherapy, or biologic therapy as cancer therapy within 3 weeks prior to initiation of ipatasertib treatment.
• Use of strong CYP3A4 inhibitors within 4 weeks prior to initiation of ipatasertib treatment.
• Oral endocrine therapy within 2 weeks prior to initiation of ipatasertib treatment.
• Prior treatment with a PI3-kinase inhibitor in which the patient experienced a Grade >= 3 drug-related adverse event or otherwise would be at increased risk for additional PI3K-related toxicity.
• Palliative radiation to bony metastases within 2 weeks prior to initiation of ipatasertib treatment.
• Radiotherapy (other than palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of ipatasertib treatment.
• Treatment with an investigational agent within 4 weeks prior to initiation of ipatasertib treatment.
• Unresolved toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy.
• Pregnant or lactating.
• Inability to comply with study and follow-up procedures.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumors

Intervention

Drug:
• Ipatasertib
Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai City

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC (0-inf) after a single dose and AUC (0-24) after single and multiple doses of Ipatasertib		Up to 25 months
Primary	Maximum plasma concentration (Cmax) of Ipatasertib		Up to 25 months
Primary	Minimum plasma concentration (Cmin) of Ipatasertib after multiple doses of Ipatasertib		Up to 25 months
Primary	Time to maximum plasma concentration (tmax) of Ipatasertib		Up to 25 months
Primary	Terminal half-life (t1/2) of Ipatasertib and GO37220		Up to 25 months
Primary	Apparent clearance (CL/F) of Ipatasertib and GO37220 after single and multiple doses of Ipatasertib		Up to 25 months
Primary	Accumulation ratio at steady state (Rcmax) of Ipatasertib	Accumulation ratio will be calculated as follows: Rcmax = AUC24h,ss/AUC0-24 of Day 1.	Up to 25 months
Secondary	Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)	Assessed by the NCI CTCAE v5.0 criteria.	Up to 25 months
Secondary	Percentage of Participants with Adverse Events leading to Study Treatment Discontinuation, Modification or Interruption		Up to 25 months
Secondary	Number of Deaths		Up to 25 months